Carrier Is Water Suspendible Particles (e.g., Latex, Etc.) Patents (Class 436/533)
  • Patent number: 10267789
    Abstract: An object of the present invention is to provide a method of reducing interference to a measurement system from water-soluble silicone and/or surfactant contaminating the measurement system in a latex agglutination immunoassay. The execution of a latex immunoagglutination reaction in the presence of a silicone compound can reduce the interference to the measurement system from a component derived from a micro blood-collection tube (water-soluble silicone) and/or surfactant mixed from outside of the measurement system.
    Type: Grant
    Filed: March 31, 2011
    Date of Patent: April 23, 2019
    Assignee: SEKISUI MEDICAL CO., LTD.
    Inventors: Hiroshi Takahashi, Yuki Takahashi, Kazunori Saito
  • Patent number: 10101325
    Abstract: An assay method for the detection of potential for CVD or propensity to CVD in a human or non-human animal subject, said method comprising assessing the concentration of calprotectin in a calprotectin-containing sample taken from said subject.
    Type: Grant
    Filed: December 22, 2003
    Date of Patent: October 16, 2018
    Assignee: SUNDREHAGEN, ERLING, DR.
    Inventor: Erling Sundrehagen
  • Patent number: 9465033
    Abstract: A latex particle for high-sensitive agglutination assay and a reagent for agglutination assay including the particle are provided. The latex particle barely initiates non-specific reactions and can readily prepare diagnostic agents. A latex particle for agglutination assay including a polymerizable monomer having a phenyl group, a polymerizable monomer having a phenyl group and a salt of sulfonic acid, and a polymerizable monomer represented by Formula (1): CH2?CR1—COO(CH2CH2O)n—R2??(1) where R1 represents a hydrogen atom or a methyl group; R2 represents a hydrogen atom or a methyl group; and n is 1?n<20, wherein the density of functional groups derived from the polymerizable monomer represented by Formula (1) on the surface of the particle is 0.05 to 0.5 ?mol/m2.
    Type: Grant
    Filed: April 1, 2013
    Date of Patent: October 11, 2016
    Assignee: SEKISUI MEDICAL CO., LTD.
    Inventors: Shinichiro Kitahara, Yuki Takahashi
  • Patent number: 9233173
    Abstract: The invention relates to tumour therapy. In one aspect, the present invention relates to conjugates of a toxin and a target-binding moiety, e.g. an antibody, which are useful in the treatment of cancer. In particular, the toxin is an amatoxin, and the target-binding moiety is preferably directed against tumour-associated antigens. In particular, the amatoxin is conjugated to the antibody by linker moieties. In particular the linker moieties are covalently bound to functional groups located in positions of the amatoxin proved as preferred positions for the attachment of linkers with respect to optimum antitumor activity. In a further aspect the invention relates to pharmaceutical compositions comprising such target-binding moiety toxin conjugates and to the use of such target-binding moiety toxin conjugates for the preparation of such pharmaceutical compositions. The target-binding moiety toxin conjugates and pharmaceutical compositions of the invention are useful for the treatment of cancer.
    Type: Grant
    Filed: April 8, 2010
    Date of Patent: January 12, 2016
    Assignees: Deutsches Krebsforschungszentrum, Heinz Faulstich
    Inventors: Heinz Faulstich, Gerhard Moldenhauer, Werner Simon, Jan Anderl, Christoph Müller
  • Patent number: 9187690
    Abstract: The present invention provides a rare earth metal complex represented by the following formula (I).
    Type: Grant
    Filed: March 12, 2012
    Date of Patent: November 17, 2015
    Assignee: B.R.A.H.M.S. GmbH
    Inventors: Mikio Hoshino, Toshisada Yano, Yasukazu Yamanaka
  • Patent number: 9005995
    Abstract: The present invention relates to a nanoscale or microscale particle for encapsulation and delivery of materials or substances, including, but not limited to, cells, drugs, tissue, gels and polymers contained within the particle, with subsequent release of the therapeutic materials in situ, methods of fabricating the particle by folding a 2D precursor into the 3D particle, and the use of the particle in in-vivo or in-vitro applications. The particle can be in any polyhedral shape and its surfaces can have either no perforations or nano/microscale perforations. The particle is coated with a biocompatible metal, e g gold, or polymer e g parvlene, layer and the surfaces and hinges of the particle are made of any metal or polymer combinations.
    Type: Grant
    Filed: March 6, 2014
    Date of Patent: April 14, 2015
    Assignee: The Johns Hopkins University
    Inventors: David H. Gracias, Timothy Gar-Ming Leong, Hongke Ye
  • Patent number: 8987005
    Abstract: [PROBLEMS] To provide a reagent for measuring agglutination by using a reaction accelerator, which causes no spontaneous agglutination of receptor-sensitized carrier particles in the coexistence of these carrier particles, and a measurement method. [MEANS FOR SOLVING PROBLEMS] A reagent for measuring agglutination by using a specific amine compound, whereby aggregation based on a specific reaction can be accelerated without causing spontaneous agglutination of carrier particles, and measurement method.
    Type: Grant
    Filed: December 27, 2006
    Date of Patent: March 24, 2015
    Assignee: Sekisui Medical Co., Ltd.
    Inventors: Mitsuaki Yamamoto, Tadaaki Yoshida
  • Patent number: 8940525
    Abstract: Disclosed is a simple device for a membrane assay using the lateral flow immunoassay method, whereby a subject to be detected can be detected at a high sensitivity, provided with, as a label drying pad, a substrate which has a higher tensile strength than glass fiber and can well release a label. The present invention provides a simple membrane assay device, comprising: a supporting board, a sample supply part, a label containing a labeling component which labels a subject to be detected, a development part formed with a detection part which includes a trapping reagent for detecting or quantifying the subject to be detected, and an absorption part, wherein a non-woven fabric which includes fibers having a fiber diameter of 0.05 to 10 ?m is used in the labeling component part.
    Type: Grant
    Filed: October 27, 2011
    Date of Patent: January 27, 2015
    Assignee: Denko Seiken Co., Ltd.
    Inventors: Takanori Hirose, Koichi Inano, Hideharu Simizu
  • Patent number: 8716033
    Abstract: The present invention generally relates to methods of functionalizing proteins, particularly antibodies, at oligosaccharide linkages, methods of humanizing antibodies by modifying glycosylation, as well as to novel antibodies linked to modified oligosaccharides. The invention further relates to kits that may be used to produce the antibodies of the invention.
    Type: Grant
    Filed: February 12, 2007
    Date of Patent: May 6, 2014
    Assignee: Life Technologies Corporation
    Inventors: Brian Agnew, Schuyler B. Corry, Kyle R. Gee
  • Patent number: 8709829
    Abstract: The present invention relates to a nanoscale or microscale particle for encapsulation and delivery of materials or substances, including, but not limited to, cells, drugs, tissue, gels and polymers contained within the particle, with subsequent release of the therapeutic materials in situ, methods of fabricating the particle by folding a 2D precursor into the 3D particle, and the use of the particle in in-vivo or in-vitro applications The particle can be in any polyhedral shape and its surfaces can have either no perforations or nano/microscale perforations The particle is coated with a biocompatible metal, e g gold, or polymer e g parvlene, layer and the surfaces and hinges of the particle are made of any metal or polymer combinations.
    Type: Grant
    Filed: August 20, 2012
    Date of Patent: April 29, 2014
    Assignee: The Johns Hopkins University
    Inventors: David H. Gracias, Timothy Gar-Ming Leong, Hongke Ye
  • Patent number: 8580559
    Abstract: The present invention provides a cartridge for analyzing a fluid sample. The cartridge provides for the efficient separation of cells or viruses in the sample from the remaining sample fluid, lysis of the cells or viruses to release the analyte (e.g., nucleic acid) therefrom, and optionally chemical reaction and/or detection of the analyte. The cartridge is useful in a variety of diagnostic, life science research, environmental, or forensic applications for determining the presence or absence of one or more analytes in a sample.
    Type: Grant
    Filed: October 24, 2007
    Date of Patent: November 12, 2013
    Assignee: Cepheid
    Inventors: Kurt E. Petersen, Michael T. Taylor, Farzad Pourahmadi, William A. McMillan, Ronald Chang, Stanley H. Sakai, Jesus Ching, Douglas B. Dority, Phillip Belgrader, M. Allen Northrup
  • Patent number: 8580531
    Abstract: The invention relates to a method for detecting a plurality of antigenic molecules carried by erythrocytes and/or a plurality of anti-erythrocyte antibodies, said antigenic molecules carried by the erythrocytes consisting of antigenic molecules carried not only by the erythrocytes, but also by at least one other cell population, other than the blood group antigen molecules, said method comprising bringing a sample into contact with distinguishable beads, on which are attached a) antibodies specific for said antigens, or b) erythrocytes or erythrocyte membrane fragment.
    Type: Grant
    Filed: June 6, 2008
    Date of Patent: November 12, 2013
    Assignee: Bio-Rad Innovations
    Inventors: Frederic Buffiere, Yves Raisin, Eliane Rivalin, Amparo Sanjuan
  • Patent number: 8580530
    Abstract: The invention relates to a method for detecting a plurality of antigenic molecules carried by erythrocytes and/or a plurality of anti-erythrocyte antibodies of an individual, comprising bringing a sample into contact with distinguishable beads, on which are attached a) antibodies specific for said antigens, or b) erythrocytes, erythrocyte membrane fragments or blood group antigens.
    Type: Grant
    Filed: June 6, 2008
    Date of Patent: November 12, 2013
    Assignee: Bio-Rad Innovations
    Inventors: Frederic Buffiere, Yves Raisin, Eliane Rivalin, Amparo Sanjuan
  • Patent number: 8563329
    Abstract: Modified branched polymers are combined with bioactive agents which are one member of a binding pair for use in an assay.
    Type: Grant
    Filed: May 2, 2006
    Date of Patent: October 22, 2013
    Assignee: ANP Technologies, Inc.
    Inventors: Ray Yin, Dujie Qin, Jing Pan
  • Patent number: 8551786
    Abstract: Systems and methods for enhancing fluorescent detection of target molecules in a test sample are for use with an irradiating device. First fluorophores are provided for absorption of EMF radiation, and emission of a first signal. Second fluorophores are provided for partial absorption of the first signal, and emission of a second signal distinguishable from the first signal. The fluorophores are combined with the test sample, and secured to the target molecules and relative to one another. After the first fluorophores receive the EMF radiation from the irradiating device, the first signal is detected, together with the second spectral signal if the target molecules are present in the test sample.
    Type: Grant
    Filed: July 9, 2008
    Date of Patent: October 8, 2013
    Assignee: FIO Corporation
    Inventors: Warren Che Wor Chan, Travis Leon Jennings, Jesse M. Klostranec
  • Patent number: 8513024
    Abstract: Provided is a detection method for a target substance capable of enhancing detection sensitivity and quantitative property of a magnetic biosensor, while keeping monodispersity and dispersion stability of magnetic markers, including the steps of: reacting the target substance in a sample solution with a first target substance trapping member immobilized on a sensing element and with a second target substance trapping member immobilized on a gel particle to hold the gel particle on the sensing element; adjusting a magnetic marker precursor including the gel particle and a magnetic material precursor existing in the gel particle by bringing the magnetic material precursor into contact with the gel particle; synthesizing a magnetic material from the magnetic material precursor held on the gel particle, thereby adjusting the magnetic markers; and detecting the magnetic markers with the sensing element.
    Type: Grant
    Filed: February 4, 2009
    Date of Patent: August 20, 2013
    Assignee: Canon Kabushiki Kaisha
    Inventor: Kazumichi Nakahama
  • Patent number: 8507094
    Abstract: The present invention relates to a composite bead and a fabrication method thereof, and particularly, to a porous composite bead comprising superparamagnetic cluster and nanoparticles, such as light-emitting nanoparticles, magnetic nanoparticles, metallic nanoparticles, metal oxide nanoparticles and the like, and a fabrication method thereof.
    Type: Grant
    Filed: December 28, 2010
    Date of Patent: August 13, 2013
    Assignee: Korea Institute of Science and Technology
    Inventors: Kyoungja Woo, Wooyoung Park
  • Patent number: 8456158
    Abstract: A magnetic binding substance, which is a first binding substance that specifically binds with a target substance, having magnet enveloping dielectric particles, which have magnetic particles enveloped therein and surfaces modified with functional groups that exhibit polarity within a liquid sample, attached thereto, and a labeling binding substance, which is a second binding substance that specifically binds with the target substance having photoresponsive labels attached thereto, are mixed with the liquid sample such that binding reactions occur. A magnetic field is generated within a sample cell, to draw the magnetic binding substance to a local region. Excitation light is irradiated only onto a predetermined region including the local region while the magnetic binding substance is drawn to the local region, causing the photoresponsive labels present therein to generate optical signals. The optical signals are detected.
    Type: Grant
    Filed: July 28, 2010
    Date of Patent: June 4, 2013
    Assignee: FUJIFILM Corporation
    Inventor: Hisashi Ohtsuka
  • Patent number: 8415173
    Abstract: A gel microdrop composition is provided. In certain embodiments, the gel microdrop composition contains a polymer matrix, an effector particle that releases an effector molecule into the polymer matrix, a first reporter particle that emits a first optically detectable signal and a second reporter particle that emits a second optically detectable signal that is distinguishable from the first optically detectable signal, where the effector particle and said first and second reporter particles are encapsulated by the polymer matrix. Methods of screening that employ the gel microdrop composition and methods of making the gel microdrop composition are also disclosed.
    Type: Grant
    Filed: August 26, 2011
    Date of Patent: April 9, 2013
    Assignee: Crystal Bioscience Inc.
    Inventor: William Don Harriman
  • Patent number: 8354238
    Abstract: A method of assaying a sample with the use of the aggregation reaction of immunological microparticles and an assay kit. The assay is conducted by using microparticles wherein the same or an analog of the analyte and a substance that specifically binds to a substance that can specifically bind to the analyte are both bound to an insoluble carrier. Thus, it becomes possible to conveniently carry out the assay even in the case where the analyte has only a small number of specific binding sites, without especially adding a competitive substance carrying hapten bonded thereto to the reaction system so as to induce simultaneous competition of the target substance and the competitive substance.
    Type: Grant
    Filed: November 10, 2008
    Date of Patent: January 15, 2013
    Assignee: Alfresa Pharma Corporation
    Inventors: Mari Yanagiya, Mutsumi Tanaka, Mieko Kosaka, Masayasu Enomoto
  • Patent number: 8354235
    Abstract: The invention concerns a method for increasing the dynamic measuring range of especially immunological test elements in particular immunological chromatography test strips that can be evaluated optically that are based on specific binding reactions. The invention enables the dynamic measuring range of test elements based on specific binding reagents, especially of immunological test elements to be shifted towards higher analyte concentrations without impairing the lower detection limit.
    Type: Grant
    Filed: November 7, 2006
    Date of Patent: January 15, 2013
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Ludger Bodenbach, Juergen Schaeffler, Juergen Spinke
  • Patent number: 8182746
    Abstract: An electrophoresis apparatus is generally disclosed for sequentially analyzing a single sample or multiple samples having one or more analytes in high or low concentrations. The apparatus comprises a relatively large-bore transport capillary which intersects with a plurality of small-bore separation capillaries and includes a valve system. Analyte concentrators, having antibody-specific (or related affinity) chemistries, are stationed at the respective intersections of the transport capillary and separation capillaries to bind one or more analytes of interest. The apparatus allows the performance of two or more dimensions for the optimal separation of analytes. The apparatus may also include a plurality of valves surrounding each of the analyte concentrators to localize each of the concentrators to improve the binding of one or more analytes of interest.
    Type: Grant
    Filed: October 31, 2007
    Date of Patent: May 22, 2012
    Assignee: Princeton Biochemicals, Inc.
    Inventor: Norberto A. Guzman
  • Patent number: 8137985
    Abstract: A flow-through assay for detecting the quantity of an analyte residing in a test sample is provided. The flow-through assay contains a porous membrane that is in fluid communication with probe conjugates that contain a specific binding member and a detectable probe. The porous membrane also defines a detection zone and a calibration zone. The calibration zone contains a polyelectrolyte substantially non-diffusively immobilized on the porous membrane. The polyelectrolyte is capable of generating a detectable calibration signal that can be readily compared (visually, quantitatively, and the like) to a detection signal to determine the amount of analyte in the test sample.
    Type: Grant
    Filed: November 12, 2009
    Date of Patent: March 20, 2012
    Assignee: Kimberly-Clark Worldwide, Inc.
    Inventors: Xuedong Song, Ning Wei, Curtis N. Sayre
  • Patent number: 8110403
    Abstract: It is an object of the present invention to provide an immunoassay method which is capable of simultaneous quantification of a plurality of test substances under a same analysis condition, through adjustment of the measurement sensitivity/range by simply varying the size of particles for use as labels, without changing the spectra of these particles.
    Type: Grant
    Filed: February 11, 2009
    Date of Patent: February 7, 2012
    Assignee: Fujifilm Corporation
    Inventors: Tadahiro Matsuno, Kentaro Nakamura
  • Patent number: 8101429
    Abstract: This invention is directed to a lateral flow assay for detecting the presence of an analyte in a liquid test sample. The lateral flow assay represents an improvement in the ability to accurately and with high fidelity to detect the presence or absence of a target analyte in a liquid sample, in part, by encompassing a reference region of immobilized, non-diffusible analyte that allows for detection of any factors that interfere with the interaction and binding of the analyte to the labeled capture reagent. Any influences on the interaction and binding of the analyte that is free in solution in the liquid test sample to its complementary labeled reagent will be encountered in parallel in the binding between the immobilized analyte in reference region to the labeled reagent as it diffuses through the reference region. In one embodiment, the lateral flow assay of the invention is a urine-based human Chorionic Gonadotropin (hCG) assay.
    Type: Grant
    Filed: June 3, 2004
    Date of Patent: January 24, 2012
    Assignee: Siemens Healthcare Diagnostics Inc.
    Inventors: Gary H. Krauth, David J. Ledden
  • Patent number: 8034397
    Abstract: Hollow particles for use in various types of assay devices are provided. Due to their hollow or voided structure, the particles may exhibit a variety of beneficial properties. For instance, hollow particles are generally lightweight, and thus, relatively inexpensive in comparison to other types of particles. Hollow particles may also form a stable system without requiring refrigeration or rotation. In addition, hollow particles may possess enhanced light diffraction capabilities, which may be particularly beneficial in certain types of assay devices, e.g., diffraction-based assay devices.
    Type: Grant
    Filed: September 28, 2010
    Date of Patent: October 11, 2011
    Assignee: Kimberly-Clark Worldwide, Inc.
    Inventors: Kaiyuan Yang, Ning Wei, Rosann Kaylor, Chibueze Obinna Chidebelu-Eze, Zdravko Savov Atanassov
  • Patent number: 8030092
    Abstract: An electrophoresis apparatus is generally disclosed for sequentially analyzing a single sample or multiple samples having one or more analytes in high or low concentrations. The apparatus comprises a relatively large-bore transport capillary which intersects with a plurality of small-bore separation capillaries and includes a valve system. Analyte concentrators, having antibody-specific (or related affinity) chemistries, are stationed at the respective intersections of the transport capillary and separation capillaries to bind one or more analytes of interest. The apparatus allows the performance of two or more dimensions for the optimal separation of analytes. The apparatus may also include a plurality of valves surrounding each of the analyte concentrators to localize each of the concentrators to improve the binding of one or more analytes of interest.
    Type: Grant
    Filed: November 17, 2006
    Date of Patent: October 4, 2011
    Assignee: Princeton Biochemicals, Inc.
    Inventor: Norberto A. Guzman
  • Patent number: 8030091
    Abstract: A test device and method for determining the presence or absence of one or more analytes in a fluid sample, the test device including a support or member bearing a mark thereon, and a matrix or member containing a capture zone. In operation, an observation area in the test device becomes transparent, thereby allowing the user to view a mark that is present on a support that is disposed beneath the observation area. Typically, the mark on the underlying support is configured as a minus (?) sign. In the absence of analyte in the sample, the test device presents a negative result as a minus (?) signal. In the presence of analyte in the sample, however, the mark operates in concert with a perpendicular test line on the observation area to present a positive result as a plus (+) signal that is visible to the user.
    Type: Grant
    Filed: April 14, 2009
    Date of Patent: October 4, 2011
    Assignee: Quidel Corporation
    Inventors: Jeremy Jerome, Mark Daquipa, Bruce Jacono, Hans Boehringer, Paul Lambotte, Paul J. Lawrence
  • Patent number: 8030095
    Abstract: A gel microdrop composition is provided. In certain embodiments, the gel microdrop composition contains a polymer matrix, an effector particle that releases an effector molecule into the polymer matrix, a first reporter particle that emits a first optically detectable signal and a second reporter particle that emits a second optically detectable signal that is distinguishable from the first optically detectable signal, where the effector particle and said first and second reporter particles are encapsulated by the polymer matrix. Methods of screening that employ the gel microdrop composition and methods of making the gel microdrop composition are also disclosed.
    Type: Grant
    Filed: March 2, 2009
    Date of Patent: October 4, 2011
    Assignee: Crystal Bioscience Inc.
    Inventor: William Don Harriman
  • Patent number: 8026107
    Abstract: Provided are an agglutination-inhibition assay and a reagent for agglutination-inhibition assay, which can be used for measuring a ligand in a sample at high sensitivity in a wide range from the low-concentration range to the high-concentration range and have good reproducibility of measurement. Specifically, provided are an agglutination-inhibition assay and a reagent for agglutination-inhibition assay, in which used are an insoluble carrier particle carrying a ligand, a specific receptor in the free-form and an insoluble carrier particle carrying a specific receptor which binds to a different site on the ligand than the receptor in the free-form.
    Type: Grant
    Filed: July 23, 2007
    Date of Patent: September 27, 2011
    Assignee: Sekisui Medical Co., Ltd.
    Inventors: Tadaaki Yoshida, Hiroshi Takahashi
  • Patent number: 7989217
    Abstract: The subject invention is an immunoassay for the semi-quantitative test kit for determination of human chrionic gonadtropin (hCG) in fluid sample (such as urine) as an aid in the diagnosis of a certain stage of pregnancy. The test device includes five strips having each having a dipping end or sample ends where sample can be applied. Results are indicated by coloration of two bands across a clear area of the strips, one band being coated with a reagent such as hCG antigens and the other with a reagent such as goat/rabbit polyclonal antibody gold conjugate. The combination of color indications on the bands provides the test results.
    Type: Grant
    Filed: March 29, 2007
    Date of Patent: August 2, 2011
    Assignee: AmeriTek USA, Inc.
    Inventors: Hsiao-Ching Yee, Kuo-Ching Yee, Hsian-Pei Yee
  • Patent number: 7981690
    Abstract: By using an antibody which is covalently bonded to a water soluble polymer as an antibody to be used in a competitive immunoagglutination assay in a homogeneous system, a protein antigen at a high concentration can be accurately assayed in an undiluted system without resorting to dilution.
    Type: Grant
    Filed: November 10, 2006
    Date of Patent: July 19, 2011
    Assignee: Nitto Boseki Co., Ltd.
    Inventors: Ryo Kojima, Yoshiro Sato, Katsuhiro Katayama
  • Publication number: 20110104825
    Abstract: To provide a technique for enhancing measurement sensitivity or a technique for avoiding a hemoglobin influence in an immunoassay method. The invention is directed to a method for enhancing measurement sensitivity or a hemoglobin influence avoiding method in an immunoassay method, characterized in that the method includes assaying target substance contained in a biological sample through antigen-antibody reaction in the presence of a macrocyclic compound.
    Type: Application
    Filed: July 3, 2009
    Publication date: May 5, 2011
    Applicant: Sekisui Medical Co., Ltd.
    Inventors: Mitsuaki Yamamoto, Akiko Suzuki
  • Patent number: 7897328
    Abstract: The present invention provides compositions and methods for treating or preventing antibody mediated graft rejection and blood typing.
    Type: Grant
    Filed: March 23, 2007
    Date of Patent: March 1, 2011
    Assignee: AbSorber AB
    Inventors: Jan Holgersson, Jining Liu, Linda Lindberg, Per Grufman
  • Patent number: 7892762
    Abstract: A method for aiding in differentiating irritable bowel syndrome from inflammatory bowel disease by determining the level of total endogenous human lactoferrin in clinical specimens, such as feces, mucus and bile, wherein an elevated level of lactoferrin substantially precludes diagnoses of IBS and other noninflammatory etiologies, and a kit usable in such method are provided. Further provided is a method for quantitating the level of total endogenous human lactoferrin in clinical specimens, such as feces, mucus and bile, to monitor gastrointestinal inflammation in persons having inflammatory bowel disease.
    Type: Grant
    Filed: June 17, 2009
    Date of Patent: February 22, 2011
    Assignee: Techlab, Inc.
    Inventors: James Hunter Boone, David Maxwell Lyerly, Tracy Dale Wilkins, Richard Littleton Guerrant
  • Patent number: 7867785
    Abstract: An objective of the invention is to provide a carrier particle latex for an assay reagent capable of assaying a biological sample at a wide range of the concentration in an immunoserological test and capable of being stored stably for a prolonged period, as well as an assay reagent employing the same. The invention is a carrier particle latex for an assay reagent comprising a carrier particle comprising a copolymer of a polymerizable monomer having a phenyl group and a polymerizable monomer having a phenyl group and a sulfonate, wherein said carrier particle has a surface sulfonic acid group amount of 0.005 to 0.7 ?mol/m2 and an average particle size of 0.01 to 1.5 ?m.
    Type: Grant
    Filed: January 3, 2008
    Date of Patent: January 11, 2011
    Assignee: Sekisui Medical Co., Ltd.
    Inventor: Satoshi Obana
  • Patent number: 7858396
    Abstract: A lateral flow test strip for the analysis of a sample featuring numerous capture zones arranged in an array such that each capture zone is substantially equidistant from the sample containing area. The sample does not pass through another capture zone to reach any one of the other capture zones. The capture zones are preferably arranged in a linear array perpendicular to the flow of the sample through the lateral flow test strip. The lateral flow test strip allows for an increased number of simultaneous analyses of numerous analytes from one sample to occur on one lateral flow test strip.
    Type: Grant
    Filed: October 31, 2006
    Date of Patent: December 28, 2010
    Assignee: Orasure Technologies, Inc.
    Inventors: Paul L.A.M. Corstjens, Keith Kardos, R. Sam Niedbala, Hans J. Tanke, Michel Zuiderwijk, Hans H. Feindt, Vijay K. Mokkapati, Jess Aaron Kimball
  • Patent number: 7858399
    Abstract: The present invention relates to immobilized procainamide analogs, as well as to a method of making immobilized procainamide analogs. These immobilized analogs are prepared by activating the carboxyl group on a substituted p-benzoic acid derivative toward nucleophilic attack; reacting the activated benzoic acid derivative with a polyamine to produce the benzoic acid derivative of Formula 3: and binding the benzoic acid derivative of Formula 3 to a latex polymer having functional groups that react with aliphatic amino groups. A method of conducting an immunoassay using the immobilized procainamide analog Formula 3 is described, comprising the steps of preparing a solution comprising said immobilized procainamide analog; adding a sample suspected of containing procainamide to said solution; adding an anti-procainamide antibody to said solution and observing the rate of increase in solution turbidity following antibody addition.
    Type: Grant
    Filed: August 28, 2007
    Date of Patent: December 28, 2010
    Assignee: Siemens Healthcare Diagnostics Inc.
    Inventors: Victor P. Chu, Zhu Teng, Steve P. A. Goss, Ronald A. Edwards, Kelle M. Garvey, Timothy J. Gorzynski, William D. Bedzyk
  • Patent number: 7851209
    Abstract: A membrane-based assay device for detecting the presence or quantity of an analyte residing in a test sample is provided. The device utilizes conjugated probes that contain a specific binding member for the analyte of interest. The specific binding member preferentially complexes with the analyte within a test sample when contacted therewith. Excess analyte that remains uncomplexed with the specific binding member undergoes non-specific binding, such as to a hydrophobic domain. As a result, the ability of the uncomplexed analyte to compete with the complexed analyte at the detection zone of the device is restricted. Thus, the incidence of “false negatives” is limited in a simple, efficient, and relatively inexpensive manner.
    Type: Grant
    Filed: April 3, 2003
    Date of Patent: December 14, 2010
    Assignee: Kimberly-Clark Worldwide, Inc.
    Inventors: Ning Wei, Yanbin Huang, Kaiyuan Yang
  • Patent number: 7846748
    Abstract: The present invention provides methods of quantifying the amount or concentration of one or more peptides and/or proteins in one or more samples using differentially isotopically-labeled peptides and/or proteins. The invention also provides methods of identifying one or more peptides and/or proteins in one or more samples.
    Type: Grant
    Filed: April 11, 2003
    Date of Patent: December 7, 2010
    Assignee: The University of North Carolina at Chapel Hill
    Inventor: Christoph H. Borchers
  • Patent number: 7829328
    Abstract: Hollow particles for use in various types of assay devices are provided. Due to their hollow or voided structure, the particles may exhibit a variety of beneficial properties. For instance, hollow particles are generally lightweight, and thus, relatively inexpensive in comparison to other types of particles. Hollow particles may also form a stable system without requiring refrigeration or rotation. In addition, hollow particles may possess enhanced light diffraction capabilities, which may be particularly beneficial in certain types of assay devices, e.g., diffraction-based assay devices.
    Type: Grant
    Filed: May 25, 2006
    Date of Patent: November 9, 2010
    Assignee: Kimberly-Clark Worldwide, Inc.
    Inventors: Kaiyuan Yang, Ning Wei, Rosann Kaylor, Chibueze Obinna Chidebelu-Eze, Zdravko Savov Atanassov
  • Patent number: 7829347
    Abstract: A diagnostic test kit that provides an integrated system for accurately detecting a test analyte over a broad range of possible concentrations is provided. One feature of the integrated system is that it is capable of indicating whether an analyte is within the “hook effect” region. Based on this indication, a technique may be selected for correlating a measured signal intensity to an analyte concentration or range of concentrations. For example, when it is determined that the test sample falls outside the “hook effect” region, the analyte concentration may be determined using one portion of a dose response curve. On the other hand, when it is determined that the test sample falls within the “hook effect” concentration, the analyte concentration may be determined using another portion of the dose response curve. Alternatively, the sample may simply be diluted for re-performing the assay.
    Type: Grant
    Filed: August 31, 2005
    Date of Patent: November 9, 2010
    Assignee: Kimberly-Clark Worldwide, Inc.
    Inventor: Xuedong Song
  • Patent number: 7795041
    Abstract: The present invention relates to multi-polymer-coated magnetic nanoclusters, aqueous magnetic fluids comprising same, and methods of their use in separation procedures. The multi-polymer-coated magnetic nanoclusters comprise a super paramagnetic core, with a first polymer attached thereto, which does not render the first polymer-super paramagnetic particle complex colloidally stable, and a second polymer attached thereto, which stabilizes the complex of multi-polymer-coated magnetic nanoparticles. Methods of use comprise methods of separation, including separation of expressed protein from cells and viruses expressing the same.
    Type: Grant
    Filed: February 9, 2005
    Date of Patent: September 14, 2010
    Assignee: Massachusetts Institute of Technology
    Inventors: T. Alan Hatton, Daniel I. C. Wang, Paul Laibinis, Andre Ditsch
  • Publication number: 20100216257
    Abstract: A latex agglutination method by which the measurement range is extended and the sensitivity of the measurement in the low concentration range is increased, is disclosed. The method for measuring a test antigen by latex agglutination uses two types of large and small particles, having different average particle sizes. Each latex particle is sensitized with an antibody which undergoes antigen-antibody reaction with the test antigen. The purity of the antibody immobilized on the latex particles is within a specific range. The ratio of the amount of the antibody immobilized per one small latex particle to the amount of the antibody immobilized per one large latex particle; the average particle size of the large latex particles; the average particle size of the small latex particles; the concentration of the large sensitized latex particles in the antigen-antibody reaction system; and the concentration of the small sensitized latex particles in the reaction system are within a specific range.
    Type: Application
    Filed: February 19, 2010
    Publication date: August 26, 2010
    Applicant: DENKA SEIKEN CO., LTD.
    Inventors: Shosaku MOTODA, Yasunori Minakawa
  • Publication number: 20100197042
    Abstract: A reagent for immunological analysis, comprising a suspension of latex particles having an antigen or an antibody specific for a substance to be analyzed introduced into the surface of the latex particles, produced by polymerizing a monomer in the presence of the antigen or antibody to thereby synthesize the latex particles; and a method for immunological analysis, comprising the step of bringing, in a liquid, (1) a sample suspected of containing a substance to be analyzed, into contact with (2) latex particles having an antigen or an antibody specific for the substance introduced into the surface of the latex particles, produced by polymerizing a monomer in the presence of the antigen or antibody to thereby synthesize the latex particles; are disclosed. The reagent and the method have an excellent detection sensitivity, and can avoid a nonspecific reaction which occurs in conventional methods.
    Type: Application
    Filed: October 16, 2007
    Publication date: August 5, 2010
    Applicant: MITSUBISHI KAGAKU IATRON , INC.
    Inventors: Tokio Sawai, Hiroyuki Tsubota, Tatsuo Taniguchi, Akihiro Mizuno
  • Patent number: 7759074
    Abstract: An immunological latex turbidimetry method for analyzing an antigen or antibody in a sample, comprising the steps of: (1) bringing a sample which may contain the antigen or antibody to be analyzed into contact with a protease-treated albumin; and (2) bringing a mixture obtained in the above step (1) into contact with latex particles carrying an antibody or antigen specifically reacting with the antigen or antibody to be assayed, and analyzing a turbidity caused by a latex agglutination reaction, is disclosed. Further, an immunological latex turbidimetry reagent comprising (1) a first component containing a protease-treated albumin, and (2) a second component containing latex particles carrying an antibody or antigen specifically reacting with an antigen or antibody to be assayed is also disclosed.
    Type: Grant
    Filed: May 1, 2009
    Date of Patent: July 20, 2010
    Assignee: Mitsubishi Kagaku Iatron, Inc.
    Inventors: Atsushi Miyamoto, Tokio Sawai, Takeshi Matsuya, Tsuneo Okuyama
  • Publication number: 20100167310
    Abstract: [PROBLEMS] To provide a reagent for measuring agglutination by using a reaction accelerator, which causes no spontaneous agglutination of receptor-sensitized carrier particles in the coexistence of these carrier particles, and a measurement method. [MEANS FOR SOLVING PROBLEMS] A reagent for measuring agglutination by using a specific amine compound, whereby aggregation based on a specific reaction can be accelerated without causing spontaneous agglutination of carrier particles, and measurement method.
    Type: Application
    Filed: December 27, 2006
    Publication date: July 1, 2010
    Inventors: Mitsuaki Yamamoto, Tadaaki Yoshida
  • Patent number: 7709273
    Abstract: Methods, compositions and kits are disclosed. The compositions are light emitting and comprise a polymeric matrix having dissolved therein a photoactive compound. The composition has the characteristic that, after activation of the photoactive compound, the rate of decrease in the intensity of light emission at any time during a 20-fold decrease in the intensity is proportional to the intensity of the light emission. In one embodiment the polymeric matrix is comprised of particles of about 20 nm to about 100 ?m in diameter to which is bound a specific binding pair member. The particles generally comprise a polymeric matrix having dissolved therein about 1 to about 20% by weight of a dopant. The compositions may be used in methods for determining an analyte. A combination is provided comprising (1) a medium suspected of containing the analyte, (2) and the aforementioned composition. The photoactive substance is activated and the effect of the activating on the optical properties of the combination is detected.
    Type: Grant
    Filed: November 14, 2005
    Date of Patent: May 4, 2010
    Assignee: Siemens Healthcare Diagnostics Products GmbH
    Inventors: Sharat Singh, John S. Pease, Jacqueline Sadakian, Daniel B. Wagner, Edwin F. Ullman
  • Patent number: 7691647
    Abstract: Compositions suitable for use as signal generation components of an immunoassay, and methods for their use. According to one aspect of the invention, the composition includes a carrier having a coating of an aminodextran and a metal chelate incorporated therein. The metal chelate is present in the amount of at least 0.065 ?Mole per gram of carrier, and the aminodextran coating density averaging at least about 45 ?g per milligram of carrier. In another aspect of the invention, carrier is dyed with a complex having the formula: M(L1)x(L2)y, wherein M is a metal selected from the group consisting of europium, terbium, dysprosium, samarium, osmium and ruthenium; L1 is a ligand selected from the group consisting of DPP, TOPO, TPPO; L2 comprises a ligand having the formula wherein R is one or more substituents, each substituent comprising an electron donating group; n=2-10; x=1-2; and y=2-4.
    Type: Grant
    Filed: August 4, 2006
    Date of Patent: April 6, 2010
    Assignee: Siemens Healthcare Diagnostics Inc.
    Inventors: Alan R. Craig, Zhu Teng, Richard C. Wright, Chengrong Wang
  • Patent number: 7670786
    Abstract: A membrane-based assay device for detecting the presence or quantity of an analyte residing in a test sample is provided. The device utilizes a self-calibrated magnetic binding assay format (e.g., sandwich, competitive, etc.) that includes detection probes capable of generating a detection signal (e.g., fluorescent non-magnetic particles) and calibration probes capable of generating a calibration signal (e.g., fluorescent magnetic particles). The amount of the analyte within the test sample is proportional (e.g., directly or inversely) to the intensity of the detection signal calibrated by the intensity of the calibration signal. It has been discovered that the fluidics-based device of the present invention provides an accurate, inexpensive, and readily controllable method of determining the presence of an analyte in a test sample.
    Type: Grant
    Filed: October 22, 2007
    Date of Patent: March 2, 2010
    Assignee: Kimberly-Clark Worldwide, Inc.
    Inventors: Xuedong Song, Rosann Marie Matthews Kaylor